Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Mourón S[au]:

Search results

Items: 28

1.

Randomized phase 0/I trial of the mitochondrial inhibitor ME-344 or placebo added to bevacizumab in early HER2-negative breast cancer.

Quintela-Fandino M, Morales S, Cortés-Salgado A, Manso L, Apala JV, Muñoz M, Gasol Cudos A, Salla Fortuny J, Gion M, Lopez-Alonso A, Cortés J, Guerra J, Malón D, Caleiras E, Mulero F, Mourón S.

Clin Cancer Res. 2019 Oct 9. pii: clincanres.2023.2019. doi: 10.1158/1078-0432.CCR-19-2023. [Epub ahead of print]

PMID:
31597662
2.

Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition.

Quintela-Fandino M, Apala JV, Malon D, Mouron S, Hornedo J, Gonzalez-Cortijo L, Colomer R, Guerra J.

Breast Cancer Res. 2019 May 24;21(1):69. doi: 10.1186/s13058-019-1152-x.

3.

In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer.

Zagorac I, Fernandez-Gaitero S, Penning R, Post H, Bueno MJ, Mouron S, Manso L, Morente MM, Alonso S, Serra V, Muñoz J, Gómez-López G, Lopez-Acosta JF, Jimenez-Renard V, Gris-Oliver A, Al-Shahrour F, Piñeiro-Yañez E, Montoya-Suarez JL, Apala JV, Moreno-Torres A, Colomer R, Dopazo A, Heck AJR, Altelaar M, Quintela-Fandino M.

Nat Commun. 2018 Aug 29;9(1):3501. doi: 10.1038/s41467-018-05742-z.

4.

Uncoupling fork speed and origin activity to identify the primary cause of replicative stress phenotypes.

Rodriguez-Acebes S, Mourón S, Méndez J.

J Biol Chem. 2018 Aug 17;293(33):12855-12861. doi: 10.1074/jbc.RA118.003740. Epub 2018 Jun 29.

5.

Critically short telomeres and toxicity of chemotherapy in early breast cancer.

Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, Cortes J, Moreno-Antón F, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Mouron S, Guerra J, Bermejo B, Zamora E, García-Saenz JA, Simon SP, Carrasco E, Escudero MJ, Campo R, Colomer R, Blasco MA.

Oncotarget. 2017 Mar 28;8(13):21472-21482. doi: 10.18632/oncotarget.15592.

6.

Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach.

Bueno MJ, Mouron S, Quintela-Fandino M.

Br J Cancer. 2017 Apr 25;116(9):1119-1125. doi: 10.1038/bjc.2017.69. Epub 2017 Mar 16. Review.

7.

Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics.

Navarro P, Bueno MJ, Zagorac I, Mondejar T, Sanchez J, Mourón S, Muñoz J, Gómez-López G, Jimenez-Renard V, Mulero F, Chandel NS, Quintela-Fandino M.

Cell Rep. 2016 Jun 21;15(12):2705-18. doi: 10.1016/j.celrep.2016.05.052. Epub 2016 Jun 9.

8.

Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance.

Manso L, Mourón S, Tress M, Gómez-López G, Morente M, Ciruelos E, Rubio-Camarillo M, Rodriguez-Peralto JL, Pujana MA, Pisano DG, Quintela-Fandino M.

PLoS One. 2016 May 19;11(5):e0155840. doi: 10.1371/journal.pone.0155840. eCollection 2016.

9.

Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET.

Hernández-Agudo E, Mondejar T, Soto-Montenegro ML, Megías D, Mouron S, Sanchez J, Hidalgo M, Lopez-Casas PP, Mulero F, Desco M, Quintela-Fandino M.

Mol Oncol. 2016 May;10(5):704-18. doi: 10.1016/j.molonc.2015.12.011. Epub 2015 Dec 22.

10.

Repriming of DNA synthesis at stalled replication forks by human PrimPol.

Mourón S, Rodriguez-Acebes S, Martínez-Jiménez MI, García-Gómez S, Chocrón S, Blanco L, Méndez J.

Nat Struct Mol Biol. 2013 Dec;20(12):1383-9. doi: 10.1038/nsmb.2719. Epub 2013 Nov 17.

PMID:
24240614
11.

PrimPol, an archaic primase/polymerase operating in human cells.

García-Gómez S, Reyes A, Martínez-Jiménez MI, Chocrón ES, Mourón S, Terrados G, Powell C, Salido E, Méndez J, Holt IJ, Blanco L.

Mol Cell. 2013 Nov 21;52(4):541-53. doi: 10.1016/j.molcel.2013.09.025. Epub 2013 Oct 24.

12.

Malin knockout mice support a primary role of autophagy in the pathogenesis of Lafora disease.

Knecht E, Criado-García O, Aguado C, Gayarre J, Duran-Trio L, Garcia-Cabrero AM, Vernia S, San Millán B, Heredia M, Romá-Mateo C, Mouron S, Juana-López L, Domínguez M, Navarro C, Serratosa JM, Sanchez M, Sanz P, Bovolenta P, Rodríguez de Córdoba S.

Autophagy. 2012 Apr;8(4):701-3. doi: 10.4161/auto.19522. Epub 2012 Apr 1. Review. Erratum in: Autophagy. 2012 Jul 1;8(7):1163.

13.

Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy.

Criado O, Aguado C, Gayarre J, Duran-Trio L, Garcia-Cabrero AM, Vernia S, San Millán B, Heredia M, Romá-Mateo C, Mouron S, Juana-López L, Domínguez M, Navarro C, Serratosa JM, Sanchez M, Sanz P, Bovolenta P, Knecht E, Rodriguez de Cordoba S.

Hum Mol Genet. 2012 Apr 1;21(7):1521-33. doi: 10.1093/hmg/ddr590. Epub 2011 Dec 20. Erratum in: Hum Mol Genet. 2012 Oct 1;21(19):4366.

PMID:
22186026
14.

RINGO C is required to sustain the spindle-assembly checkpoint.

Mourón S, de Cárcer G, Seco E, Fernández-Miranda G, Malumbres M, Nebreda AR.

J Cell Sci. 2010 Aug 1;123(Pt 15):2586-95. doi: 10.1242/jcs.059964. Epub 2010 Jul 6.

15.

Negative regulation of cell-cycle progression by RINGO/Speedy E.

Dinarina A, Ruiz EJ, O'Loghlen A, Mouron S, Perez L, Nebreda AR.

Biochem J. 2008 Mar 15;410(3):535-42.

PMID:
18072937
16.

Genotoxic effects of benzo[a]pyrene and dibenzo[a,l]pyrene in a human lung cell line.

Mourón SA, Grillo CA, Dulout FN, Golijow CD.

Int J Toxicol. 2006 Jan-Feb;25(1):49-55.

PMID:
16510357
17.

Induction of DNA strand breaks, DNA-protein crosslinks and sister chromatid exchanges by arsenite in a human lung cell line.

Mourón SA, Grillo CA, Dulout FN, Golijow CD.

Toxicol In Vitro. 2006 Apr;20(3):279-85. Epub 2005 Sep 6.

PMID:
16143491
18.

DNA-protein cross-links and sister chromatid exchanges induced by dimethylarsinic acid in human fibroblasts cells.

Mourón SA, Grillo CA, Dulout FN, Golijow CD.

Mutat Res. 2005 Mar 7;581(1-2):83-90. Epub 2004 Dec 25.

PMID:
15725607
19.

Chlamydia trachomatis and Human papillomavirus infections in cervical disease in Argentine women.

Golijow CD, Abba MC, Mourón SA, Laguens RM, Dulout FN, Smith JS.

Gynecol Oncol. 2005 Jan;96(1):181-6.

PMID:
15589598
20.
21.

Association of human papillomavirus viral load with HPV16 and high-grade intraepithelial lesion.

Abba MC, Mourón SA, Gómez MA, Dulout FN, Golijow CD.

Int J Gynecol Cancer. 2003 Mar-Apr;13(2):154-8.

PMID:
12657116
22.

c-myc gene amplification detected in preinvasive intraepithelial cervical lesions.

Golijow CD, Abba MC, Mourón SA, Gómez MA, Dulout FN.

Int J Gynecol Cancer. 2001 Nov-Dec;11(6):462-5.

PMID:
11906549
23.

DNA damage by cadmium and arsenic salts assessed by the single cell gel electrophoresis assay.

Mourón SA, Golijow CD, Dulout FN.

Mutat Res. 2001 Nov 15;498(1-2):47-55.

PMID:
11673070
24.

Detection of c-erbB-2 gene amplification in cervical scrapes positive for human papillomavirus (HPV).

Golijow CD, Abba M, Mourón SA, Gómez MA, Güercci A, Dulout FN.

Cancer Invest. 2001;19(7):678-83.

PMID:
11577808
25.

[Activation of K-ras and c-erbB-2 protooncogenes in human colonic adenocarcinomas].

Golijow C, Güerci A, Mourón S, Abba M, Dulout FN, Ottino A, Pianzola H.

Acta Gastroenterol Latinoam. 2001 May;31(2):71-6. Spanish.

PMID:
11471321
26.

Association between activated K-ras and c-erbB-2 oncogenes with "high-risk" and "low-risk" human papilloma virus types in preinvasive cervical lesions.

Mourón SA, Abba MC, Güerci A, Gómez MA, Dulout FN, Golijow CD.

Mutat Res. 2000 Aug 21;469(1):127-34.

PMID:
10946249
27.
28.

Differences in K-ras codon 12 mutation frequency between "high-risk" and "low-risk" HPV-infected samples.

Golijow CD, Mourón SA, Gómez MA, Dulout FN.

Gynecol Oncol. 1999 Oct;75(1):108-12.

PMID:
10502435

Supplemental Content

Loading ...
Support Center